RIPE Knowledge Graph
RIPE-KG · Version 1.1.0 · Resource

ripekg:work/10.1111%2Fjsr.14373

https://w3id.org/ripe/ripe-kg/work/10.1111%2Fjsr.14373
SubjectPredicateObject
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study ripe:concerns ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 ripe:concerns ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study
ripekg:research-integrity-assessment/RIPEA44B073B6366CEDA7 ripe:assesses ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 ripe:concerns ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study prism:doi 10.1111/jsr.14373
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU0ED797148B4C3FB4Sonya Craig
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU278895805B1C0B87Winfried Randerath
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU2A21D8B885255E90Jean‐louis Pépin
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU2C4D71A3E57BBBB9Christian Caussé
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU329186CA7F2BFB49Yves Dauvilliers
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU3410BBA7F6BFBE5FJerryl Asin
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU3C5271891BFBABAFRumen Tiholov
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU63FC00D82558DE3DOgnian Georgiev
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU6CD1A6B900643B1BPhilippe Lehert
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAU76944148CB20EE48Maria Bonsignore
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAUAF440E44748373BCJohan Verbraecken
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAUD200A210DE4A008EFerran Barbé
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:creator ripekg:author/RIPEAUFCF789EB74D1A72BJeanne‐marie Lecomte
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study dcterms:title Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1007%2Fs40261-021-01104-8Efficacy of Pitolisant 20 mg in reducing excessive daytime sleepiness and fatigue in patients with obstructive sleep Apnoea syndrome: An individual patient data meta-analysis
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.chest.2020.03.049Efficacy of CPAP for improvements in sleepiness, cognition, mood, and quality of life in elderly patients with OSA: Systematic review and meta-analysis of randomized controlled trials
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.chest.2020.09.281HAROSA I study group. Pitolisant for residual excessive daytime sleepiness in OSA patients adhering to CPAP: A randomized trial
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.nbd.2007.12.003An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: Studies in orexinÀ/À mice and patients
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fs1474-4422%2813%2970225-4HARMONY I study group. Pitolisant versus placebo or modafinil in patients with narcolepsy: A doubleblind, randomised trial
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fs1474-4422%2816%2930333-7HARMONY-CTP study group. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: A randomised, double-blind, placebo-controlled trial
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fs2213-2600%2815%2900090-9Sleep apnoea and the brain: A complex relationship
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fs2213-2600%2819%2930198-5Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fs2213-2600%2822%2900503-3CPAP therapy for excessive daytime sleepiness and accident risk in obstructive sleep apnoea
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1038%2Fnrdp.2015.15Obstructive sleep apnoea syndrome
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1046%2Fj.1365-2869.1997.00039.xA behavioral test to assess daytime sleepiness in obstructive sleep apnoea
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1080%2F00325481.2021.1948305Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: Guidance for assessment, diagnosis, and management
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1093%2Fsleep%2F14.6.540A new method for measuring daytime sleepiness: The Epworth sleepiness scale
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1093%2Fsleep%2Fzsz174HARMONY III study group. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III study
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1111%2Fj.1365-2869.2004.00417.xComparison of the maintenance of wakefulness test (MWT) to a modified behavioral test (OSLER) in the evaluation of daytime sleepiness
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1111%2Fjsr.12039Scientific Council of the Sleep Registry of the French Federation of Pneumology-FFP. Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1111%2Fjsr.13387European guideline and expert statements on the management of narcolepsy in adults and children
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1136%2Fthoraxjnl-2018-211959Minimum important difference of the Epworth sleepiness scale in obstructive sleep apnoea: Estimation from three randomised controlled trials
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1164%2Frccm.201704-0672leThe Epworth sleepiness scale: Minimum clinically important difference in obstructive sleep apnea
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1164%2Frccm.201907-1284ocHAROSA II study group collaborators. Pitolisant for daytime sleepiness in patients with obstructive sleep apnea who refuse continuous positive airway pressure treatment. A randomized trial
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1164%2Frccm.2107065Analysis of error profiles occurring during the OSLER test: A sensitive mean of detecting fluctuations in vigilance in patients with obstructive sleep apnea syndrome
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1183%2F09031936.00016808Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: The French multicentre study
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1513%2Fannalsats.202006-696frExcessive daytime sleepiness in obstructive sleep apnea. Mechanisms and clinical management
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.1513%2Fannalsats.202205-380stThe link between obstructive sleep apnea and neurocognitive impairment: An official
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.3389%2Ffneur.2022.911996Predictors of the efficacy for daytime sleepiness in patients with obstructive sleep apnea with continual positive airway pressure therapy: A meta-analysis of randomized controlled trials
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.3390%2Fjcm10050936CPAP therapy termination rates by OSA phenotype: A French Nationwide database analysis
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/10.5664%2Fjcsm.4104The Oxford sleep resistance test (OSLER) and the multiple unprepared reaction time test (MURT) detect vigilance modifications in sleep apnea patients
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/RIPEW19E8D79A113894B5Ozawade EPAR -Public assessment report
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/RIPEW3F7B39C30BF14595Brief self-evaluation questionnaire for depressive, asthenic and anxious dimensions
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study http://purl.org/spar/cito/cites ripekg:work/RIPEWC3963D26BE21D8C9International classification of sleep disorders: Diagnostic and coding manual
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study rdf:type node1
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study rdf:type rdfs:Resource
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study rdf:type owl:Thing
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study rdf:type prov:Entity
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study rdf:type ripe:WorkWork
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study owl:sameAs https://semopenalex.org/work/W4403215013